91968-30-8

Usage

Uses

Used in Pharmaceutical Synthesis:
MDP2P is utilized as a key intermediate in the production of various pharmaceuticals, including the illicit drug MDMA (ecstasy). Its chemical structure allows for the synthesis of compounds with psychoactive properties, making it a valuable component in the development of certain medications.
Used in Controlled Substances Regulation:
Due to its potential for abuse and psychological dependence, MDP2P is regulated as a controlled substance in many countries. Its production, distribution, and use are monitored to prevent its misuse and ensure that it is only used for legitimate pharmaceutical purposes.
Used in Research and Development:
MDP2P serves as a subject of interest for researchers studying the effects of psychoactive substances on the human body. Its unique chemical properties and potential applications in drug development make it a valuable compound for scientific investigation and the advancement of pharmaceutical knowledge.

Upstream product

• 148706-30-3 2-methyl-4-methoxyphenylmagnesium bromide 
• 67-64-1 acetone 
• 917-64-6 methyl magnesium iodide 
• 24826-74-2 1-(4-methoxy-2-methylphenyl)ethanone 
• 74-88-4 methyl iodide 
• 122-46-3 3-acetoxytoluene 
• 875-59-2 4'-hydroxy-2'methylacetophenone 

Downstream Products

• 24826-73-1 4-isopropenyl-3-methyl-anisole 
• 91244-84-7 4-Methoxyphenyl-2-methyl-1-<2-chlorpropan-2> 
• 96826-35-6 C₂₂H₃₀O₂ 
• 5436-42-0 2-isopropyl-5-methoxytoluene 
• 96826-20-9 C₂₀H₂₆O₂ 

Relevant academic research and scientific papers

Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes

The syntheses of symmetrically 2,2'-disubstituted derivatives of 1,1,2,2-tetramethyl-1,2bis(4-hydroxyphenyl)ethane (1) are and of 5,5'-, and 6,6'-disubstituted derivatives of 1,1,2,2-tetramethyl-1,2-bis(3-hydroxyphenyl)ethane (6) are described (1 and 6 are strong antiestrogens with mammary tumor inhibiting activity exhibiting only slight estrogenic properties): (2,2'-substituents) F (2), Cl (3), OCH3 (4), CH3 (5); (5,5'-substituents) Cl (7); (6,6'-substituents) F (8), Cl (9), OCH3 (10), CH3 (11). The synthesis of 1-11 was accomplished by reductive coupling of the corresponding 2-phenyl-2-propanols with TiCl3 and LiAlH4. The binding affinity of the compounds to the calf uterine estrogen receptor was measured relative to that of [3H]estradiol by a competitive binding assay. With the exception of 7 and 10 all other compounds showed relative binding affinity (RBA) values between 0.5 and 6.4% that of estradiol, 2 (RBA value 6.4), and 8 and 9 (4.0 and 3.5), exceeding those of the corresponding unsubstituted 1 and 6 (3.6 and 3.0). Compounds exhibiting RBA values of >2.5% were evaluated in the mouse uterine weight test. The substituted derivatives showed an increase in uterotrophic and a decrease in antiuterotrophic activity compared to 1 and 6. Compound 2 showed a strong, dose-dependent inhibition on the DMBA-induced hormone-dependent mammary tumor of the SD-rat, exceeding that of the parent compound 1. At a dose of 5 mg/kg per day, 2 reduced total tumor area by 47% and caused a complete remission in 74% of the tumors.